1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited

19.81
AUD
+0.11
(+0.56%)
0.23EPS
78.41P/E
2.36BMarket Cap
Feb 24Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
- -
- -
0.14
- -
- -
- -
0.12
1.83
1.67
0.5
Basic EPS, GAAP
-0.18
-0.11
-0.16
-0.13
-0.02
0.03
-0.11
-0.09
-0.07
- -
1.24
1.11
0.24
Free Cash Flow per Basic Share
-0.12
-0.08
-0.15
-0.14
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.32
0.24
0.16
-0.07
0.15
0.24
0.13
0.21
0.3
0.32
1.58
2.82
2.67
Tangible Book Value per Share
0.32
0.23
0.16
-0.07
0.15
0.24
0.13
0.21
0.3
0.32
1.58
2.82
2.67
Basic Weighted Avg Shares
63
78
84
89
96
99
100
107
118
126
127
128
128
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
14
- -
- -
- -
15
232
213
65
Operating Margin (%)
- -
- -
- -
- -
- -
39.07
- -
- -
- -
-11.04
85.89
82.32
34.04
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-11
-8
-13
-12
-2
3
-11
-9
-8
- -
157
142
30
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
23.43
22.36
21.82
Profit Margin (%)
- -
- -
- -
- -
- -
22.69
- -
- -
- -
1.26
67.73
66.61
47.09
Working Capital
24
19
14
4
13
25
14
24
39
42
204
354
328
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
24
19
14
-6
15
25
14
24
39
42
205
364
338
Return on Invested Capital (%)
- -
- -
- -
- -
- -
26.73
- -
- -
- -
-3.97
107.46
42
4.62
Return on Capital (%)
- -
- -
- -
- -
- -
15.53
- -
- -
- -
0.46
127.3
49.92
8.67
Return on Common Equity (%)
-72.79
-37.84
-79.51
- -
- -
15.53
-56.16
-48.32
-24.57
0.46
127.3
49.92
8.67

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.29%
106.38%
-6.99%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
8,423.22%
17,012.88%
-78.57%
Sales/Revenue/Turnover
- -
- -
-69.69%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
232
2024
- -
- -
213
2025
- -
- -
65

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1.24
2024
- -
- -
1.11
2025
- -
- -
0.24

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jonathan Charles Pilcher
Full Time Employees
9
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
Suite 1.01, 117 Camberwell Road Melbourne VIC Australia 3123
IPO Date
Nov 23, 2004
Website
neurenpharma.com
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A (TWSE:1762)
Business
Neuren Pharmaceuticals Limited (ASX:NEU), an Australia-based biopharmaceutical company founded in 1997 and headquartered in Hawthorn East, Victoria, develops therapies for neurodevelopmental disorders that emerge in early childhood, including Rett syndrome, Fragile X syndrome, Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The company offers DAYBUE (trofinetide, NNZ-2566), approved by the US FDA in March 2023 for the treatment of Rett syndrome in adults and pediatric patients aged two years and older and commercialized worldwide by partner Acadia Pharmaceuticals Inc under exclusive license; and NNZ-2591, an investigational drug in Phase 2 clinical trials for Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome, with Acadia holding rights for Rett and Fragile X indications while Neuren retains rights for all other indications. DAYBUE generates royalty income for Neuren, with Q3 2025 net sales reported at US$101.1 million, up 11% from Q3 2024, reflecting robust US market penetration and community setting expansion, alongside H1 2025 profit after tax of A$15 million. NNZ-2591 programs carry orphan drug designations from the FDA and EMA, supporting accelerated development pathways, while Neuren advances named patient supply programs and awaits European regulatory opinions for DAYBUE.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Neuren Pharmaceuticals Limited (NURPF) Q2 2026 Earnings Call Transcript

  • defenseworld.net

    Hyperion DeFi (NASDAQ:HYPD) versus Neuren Pharmaceuticals (OTCMKTS:NURPF) Critical Survey

  • defenseworld.net

    Neuren Pharmaceuticals (OTCMKTS:NURPF) Stock Price Down 13.5% – Should You Sell?

  • seekingalpha.com

    Neuren Pharmaceuticals Limited (NURPF) Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 Transcript